Outlook Therapeutics clinical trials we track

Check company identity source

Phase 3 5 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency and Incidence of Treatment-emergent Adverse Events. After: Measure: Number of Participants With Adverse Events.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects who gain 15 or more letters in best corrected visual acuity (BCVA). After: Measure: Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluate the effectiveness of intravitreal injections of ONS-5010 compared to ranibizumab in preventing vision loss, as measured by the mean change in baseline best correct visual acuity (BCVA) at Week 8. After: Measure: Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency and incidence of treatment-emergent adverse events. After: Measure: Frequency and Incidence of Treatment-emergent Adverse Events.

Actual enrollment increased by 2 participants

Before: 195 participants (actual). After: 197 participants (actual).

Check registry source